These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 25404300)

  • 1. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
    Chang MK; Kramer I; Huber T; Kinzel B; Guth-Gundel S; Leupin O; Kneissel M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5187-95. PubMed ID: 25404300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
    Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
    Choi HY; Dieckmann M; Herz J; Niemeier A
    PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
    Leupin O; Piters E; Halleux C; Hu S; Kramer I; Morvan F; Bouwmeester T; Schirle M; Bueno-Lozano M; Fuentes FJ; Itin PH; Boudin E; de Freitas F; Jennes K; Brannetti B; Charara N; Ebersbach H; Geisse S; Lu CX; Bauer A; Van Hul W; Kneissel M
    J Biol Chem; 2011 Jun; 286(22):19489-500. PubMed ID: 21471202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Gsα in osteocytes leads to osteopenia due to sclerostin induced suppression of osteoblast activity.
    Fulzele K; Dedic C; Lai F; Bouxsein M; Lotinun S; Baron R; Divieti Pajevic P
    Bone; 2018 Dec; 117():138-148. PubMed ID: 30266511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.
    Boudin E; Yorgan T; Fijalkowski I; Sonntag S; Steenackers E; Hendrickx G; Peeters S; De Maré A; Vervaet B; Verhulst A; Mortier G; D'Haese P; Schinke T; Van Hul W
    J Bone Miner Res; 2017 Aug; 32(8):1739-1749. PubMed ID: 28477420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.
    Yee CS; Manilay JO; Chang JC; Hum NR; Murugesh DK; Bajwa J; Mendez ME; Economides AE; Horan DJ; Robling AG; Loots GG
    J Bone Miner Res; 2018 Oct; 33(10):1748-1759. PubMed ID: 29750826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
    Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
    Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
    Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
    J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
    Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
    J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.
    Moriishi T; Fukuyama R; Ito M; Miyazaki T; Maeno T; Kawai Y; Komori H; Komori T
    PLoS One; 2012; 7(6):e40143. PubMed ID: 22768243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
    Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
    Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
    Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
    J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.
    Hendrickx G; Boudin E; Mateiu L; Yorgan TA; Steenackers E; Kneissel M; Kramer I; Mortier G; Schinke T; Van Hul W
    Calcif Tissue Int; 2024 Feb; 114(2):171-181. PubMed ID: 38051321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance.
    Zhao G; Huang BL; Rigueur D; Wang W; Bhoot C; Charles KR; Baek J; Mohan S; Jiang J; Lyons KM
    J Bone Miner Res; 2018 Jun; 33(6):1076-1089. PubMed ID: 29351359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
    Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
    J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mef2c deletion in osteocytes results in increased bone mass.
    Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
    J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.
    Katchkovsky S; Chatterjee B; Abramovitch-Dahan CV; Papo N; Levaot N
    Cell Mol Life Sci; 2022 Jan; 79(2):113. PubMed ID: 35099616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.